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Spirometry is the only objective clinical tool available to phy-
sicians in the outpatient setting. Patient history is often unreli-
able and physical examinations are normal when the child 
doesn’t show symptoms. For that reason, spirometry is current-
ly considered essential for asthma diagnosis, severity stratifica-
tion, and monitoring asthma control in children ≥5 years.
1 
Bronchodilator responsiveness (BDR), which is an improvement 
of forced expiratory volume in 1 second after inhalation of   
β2-agonists, has traditionally been the definition of asthma
2 
and has recently been reported to reflect biomarkers of eosino-
philic inflammation,
3,4 bronchial hyperreactivity,
5,6 and airway 
remodeling.
7 BDR has also been regarded as a good predictor 
of response to therapy,
8 a marker for long-term prognosis,
5,9 
and an important component in defining asthma pheno-
types.
10,11
Since BDR is usually measured by changes in airflow before 
and after administration of β2-agonists, it is influenced by the 
baseline airway tone. If the airways at baseline were fully dilat-
ed by asthma treatment, airflow would barely increase. More-
over, asthmatic children usually show prebronchodilator spi-
rometry within the normal range, regardless of their symptom-
based severity of asthma control.
12 Consequently, impaired 
β-adrenergic responsiveness, which plays a role in the patho-
genesis of asthma, is rarely evident, especially when the children 
are taking controller medications.
In 1999, Hancox et al.
13 first introduced the ‘challenge-rescue’ 
technique to assess BDR. They measured BDR after broncho-
constriction induced by methacholine, because β2-receptor 
responsiveness was easier to demonstrate under conditions of 
increased bronchomotor tone. The challenge-rescue model 
has been widely used
14,15 because it has consistently provided 
evidence of bronchodilator tolerance, whereas previous studies 
of stable asthma have not. Moreover, it has obvious clinical  
relevance; asthmatics usually take β-agonists to relieve symp-
toms caused by bronchoconstriction.
16
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Despite the usefulness of this approach, some problems exist 
in terms of data interpretation. BDR to salbutamol is confound-
ed by spontaneous recovery from the bronchoconstricting  
effects of methacholine. Although spontaneous recovery for 15 
minutes after bronchoconstriction is rare,
13 other factors that 
facilitate recovery from bronchoconstriction may be displayed 
as an enhanced responsiveness to bronchodilators. On the oth-
er hand, geometric factors, such as airway mucus plugging and 
mucosal edema, might not be discerned from bronchodilator 
tolerance. Therefore, care must be taken when analyzing BDR 
data obtained from the challenge-rescue technique.
In the present issue of Allergy, Asthma, & Immunology 
Research, Bauer et al.
17 assessed BDR using the challenge-res-
cue technique and evaluated the clinical factors that may affect 
BDR in children with mild to moderate asthma. Though the  
interpretation of the data is complicated, the results provide  
interesting information. Asthmatic patients with atopy and/or 
eosinophilia displayed higher BDR as compared with that of 
non-atopic and/or non-eosinophilic patients, which provides 
indirect evidence that BDR may be a marker for inflammation. 
While admitting that bronchoconstriction induced by metha-
choline may not exactly reflect clinical exacerbation of asthma, 
the results raise the possibility that more frequent or severe 
asthma attacks would occur in non-atopic and/or non-eosino-
philic children with asthma. Another interesting finding is that 
no apparent differences were observed among the medication 
subgroups. Since inhaled long-acting β2 adrenergic agonists or 
corticosteroids were discontinued seven days prior to testing in 
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this study, it is likely that tolerance to β-agonists would no 
longer be a concern when medications are withheld for more 
than seven days. 
Assessment of BDR following induced bronchoconstriction 
may be a useful tool for evaluating impaired β-adrenergic 
responsiveness, which plays a key role in the pathogenesis of 
asthma. Further studies are needed to extend the application of 
BDR assessment to determine management options in asth-
matic patients.
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